|
Dr. Noubar Afeyan is a recognized technologist and entrepreneur, having founded and helped build several successful technology startups during the past 19 years. He is a Senior Lecturer at MIT's Sloan School of Management and is a frequent guest speaker at technology forums throughout the country. He has authored numerous scientific publications and patents. Prior to co-founding Flagship Ventures in 1999, Dr. Afeyan helped to launch six highly successful new ventures. He was the Founder, Chairman, and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field. Dr. Afeyan also served as Chairman of the Board of ChemGenics Pharmaceuticals, a privately held company spun out of PerSeptive. After PerSeptive's acquisition by Applera Corporation, Dr. Afeyan was Applera's Senior Vice President and Chief Business Officer. While at Applera, he initiated and oversaw the creation of Celera Genomics, a tracking stock subsidiary of Applera. Dr. Afeyan has also been a founding team member, investor and active board member/advisor of Antigenics, Color Kinetics and EXACT Sciences. Dr. Afeyan currently serves as a Director for Flagship portfolio companies Affinnova, BG Medicine, Codon Devices, Adnexus Therapeutics, Ensemble Discovery, Genstruct and Helicos BioSciences. In addition, he is a member of the Board of Governors of Boston University Medical School, and he is a member of several advisory boards including the Whitehead Institute at MIT, the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, the Center for Bits and Atoms at MIT's Media Lab. He is also a Board member of several economic development organizations aimed at rebuilding the former Soviet Republic of Armenia. Dr. Afeyan earned his undergraduate degree in Chemical Engineering from McGill University in Montreal and his PhD in Biochemical Engineering from the Massachusetts Institute of Technology. | 